Adalimumab biosimilar - BIOCND/Genor Biopharma

Drug Profile

Adalimumab biosimilar - BIOCND/Genor Biopharma

Alternative Names: BCD-100; GB 232; Humira biosimilar - BIOCND/Genor Biopharma

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Genor Biopharma
  • Developer Biocad; BIOCND; Genor Biopharma
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Solid tumours

Most Recent Events

  • 02 Jan 2017 Preclinical development is ongoing in China (Genor Biopharma pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in China (SC, Injection)
  • 27 Apr 2015 Phase-I clinical trials in Autoimmune disorders in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top